Advancedapplied biology
The CRISPR Babies: Gene Editing's Ethical Reckoning
Learning objectives
- Narrate the He Jiankui announcement and its immediate fallout.
- Explain the CCR5 edit and its technical shortcomings.
- Analyze why germline editing violates current ethical consensus.
- Evaluate the case's impact on governance of gene editing.
Background: The Red Line of Germline Editing
CRISPR-Cas9, adapted from a bacterial immune system, gave biology its first truly accessible gene-editing tool: a guide RNA directs the Cas9 protein to a chosen DNA sequence, where it cuts, and the cell's repair machinery creates the edit. By the mid-2010s, CRISPR had revolutionized research, and clinical trials for somatic (non-heritable) editing of blood and eye diseases were beginning — editing a patient's own cells to treat disease, with changes that die with the patient. Germline editing — altering embryos so changes pass to every cell and to future generations — was a bright red line. In 2015, an international summit concluded the science was not ready and the ethics unresolved; the consensus was clear. Then, in November 2018, on the eve of the Second International Summit on Human Genome Editing in Hong Kong, Chinese biophysicist He Jiankui released videos announcing that twin girls, Lulu and Nana, had been born from CRISPR-edited embryos — the world's first gene-edited babies. He later reported a third edited child. The announcement stunned the world.
The CRISPR babies case is about the difference between what technology can do and what ethics permits — and what happens when one person ignores that difference.
What Happened: The Announcement and the Fallout
He's team had used CRISPR to disable CCR5, a receptor HIV uses to enter immune cells, aiming to confer HIV resistance. The children's father was HIV-positive. But the scientific case collapsed under scrutiny. The edits appeared mosaic — present in some cells but not others — meaning the intended protection was uncertain. Off-target edits elsewhere in the genome could not be excluded. There was no medical necessity: the father's HIV status posed no transmission risk to the children through standard IVF precautions, and HIV is preventable and treatable by established means. The consent process was judged inadequate, the work was conducted in secrecy without proper ethical review, and the children — who could not consent — now carry heritable genetic alterations of unknown consequence. The reaction was swift and near-universal: scientists worldwide, including in China, condemned the experiment; He's university disavowed him; and in December 2019 a Chinese court sentenced him to three years in prison for illegal medical practice. International bodies intensified calls for a moratorium on clinical germline editing.
The Biological Mechanism: Why Embryo Editing Is Different
The technical objections to He's experiment illustrate why germline editing remains off-limits. CRISPR in embryos faces mosaicism: editing may occur after the first cell divisions, producing a patchwork individual in which some cells carry the edit and others do not — defeating the purpose and complicating every outcome. Off-target cuts — Cas9 cutting at similar-but-wrong sequences — risk disrupting essential genes or activating oncogenes, with consequences lasting a lifetime and transmitted to descendants. The CCR5 target itself was questionable: disabling it does not guarantee HIV resistance (some HIV strains use other receptors), and CCR5 has roles in normal immunity — people lacking it may be more vulnerable to certain other infections. These are not abstract risks but measurable uncertainties that somatic therapies avoid by treating consenting patients for serious diseases. The ethical structure is equally clear: germline edits are intergenerational experiments on people who cannot consent, for enhancements or preventions achievable by safer means, crossing from medicine into eugenics-adjacent territory that societies have repeatedly rejected.
Outcome and Lessons: The Scandal That Drew the Line
The He's case became bioethics' defining scandal of the genomic era, and its effects endure. It hardened the global consensus: major scientific academies, the WHO, and national bodies maintain that clinical germline editing should not proceed, and many jurisdictions moved to strengthen oversight. It also clarified the governance gap — that norms without enforcement fail when a single actor defects — spurring proposals for international registries, clearer red lines, and consequences. For the science itself, the case was a setback, chilling legitimate discussion of germline editing's distant future while somatic CRISPR therapies advanced to genuine clinical successes. For students, the case is the essential study in scientific responsibility: technical capability does not confer ethical permission, secrecy is a warning sign, and the people most affected — here, children — must be at the center of the moral analysis. The question it poses will outlive its perpetrator: who decides what kind of humans we become?
Exam Angle: Facts First, Then Ethics
CRISPR baby questions demand factual precision and ethical clarity. State the facts: November 2018 announcement, twins Lulu and Nana, CCR5 targeted for HIV resistance, third child later reported, three-year prison sentence in 2019. For the science, explain mosaicism and off-target effects as the core safety objections, and note the lack of medical necessity. For the ethics, structure around consent (the children could not consent), heritability (changes pass to descendants), and proportionality (no serious disease, safer alternatives existed). Distinguish somatic editing (treating a patient, changes not inherited) from germline editing (heritable, affecting future generations) — this distinction is the foundation of the entire debate. Present the global response factually: widespread condemnation and strengthened governance efforts.
Somatic editing treats a consenting patient; germline editing alters future generations. Ethics treats these as fundamentally different acts.
Key points
- In November 2018, He Jiankui announced the birth of twins with CRISPR-edited embryos.
- He targeted CCR5, aiming for HIV resistance — not treatment of a serious disease.
- The edits were reportedly mosaic and off-target effects could not be ruled out.
- The announcement drew near-universal condemnation from scientists worldwide.
- He was sentenced to three years in prison; the case intensified calls for germline-editing governance.
Common misconceptions
✓ Truth: There was no disease to cure. The stated goal was HIV resistance — achievable by far safer means — in children of an HIV-positive father, where standard precautions already prevent transmission.
✓ Truth: Embryo editing risks mosaicism (some cells edited, others not) and off-target cuts with lifelong, heritable consequences. These safety gaps are why clinical germline editing is widely considered premature.
✓ Truth: The reaction was overwhelmingly condemnatory, including from Chinese scientists and institutions. Major academies called for a moratorium on clinical germline editing.
Frequently asked questions
What is CRISPR-Cas9?
CRISPR-Cas9 is a gene-editing system adapted from bacterial immunity. A guide RNA directs the Cas9 protein to a matching DNA sequence, where it cuts; the cell's repair then creates the edit.
What gene did He Jiankui edit, and why?
He attempted to disable CCR5, a cell-surface receptor HIV uses to enter immune cells, aiming to make the children resistant to HIV. The edits were reportedly incomplete and mosaic.
Why was the experiment condemned?
Germline edits are heritable — they pass to future generations — and were made without medical need, with inadequate safety data, in secret. The global consensus holds germline editing is not ready for clinical use.
What happened to He Jiankui?
In 2019 a Chinese court sentenced He to three years in prison for illegal medical practice. The verdict reflected both the ethical breach and violations of Chinese regulations.